Codexis, Inc. v. Enzymeworks, Inc.

CourtCourt of Appeals for the Federal Circuit
DecidedFebruary 8, 2019
Docket18-1655
StatusUnpublished

This text of Codexis, Inc. v. Enzymeworks, Inc. (Codexis, Inc. v. Enzymeworks, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Codexis, Inc. v. Enzymeworks, Inc., (Fed. Cir. 2019).

Opinion

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

CODEXIS, INC., Plaintiff-Appellee

v.

ENZYMEWORKS, INC., SUZHOU HANMEI BIOTECHNOLOGY CO. LTD, DBA ENZYMEWORKS, INC. (CHINA), JUNHUA TAO, ANDREW TAO, Defendants-Appellants ______________________

2018-1655 ______________________

Appeal from the United States District Court for the Northern District of California in No. 3:16-cv-00826-WHO, Judge William H. Orrick, III. ______________________

Decided: February 8, 2019 ______________________

DOUGLAS ETHAN LUMISH, Latham & Watkins LLP, Menlo Park, CA, for plaintiff-appellee. Also represented by GABRIEL GROSS; GABRIEL BELL, Washington, DC.

J. JAMES LI, LiLaw, Inc., Los Altos, CA, for defendants- appellants. Also represented by ANDY PIERZ. ______________________ 2 CODEXIS, INC. v. ENZYMEWORKS, INC.

Before DYK, CHEN, and HUGHES, Circuit Judges. PER CURIAM. EnzymeWorks, Inc., Suzhou Hanmei Biotechnology Co., d/b/a EnzymeWorks, Inc. (China), Junhua Tao, and Andrew Tao (collectively “EnzymeWorks”) appeal from or- ders of the U.S. District Court for the Northern District of California. The district court imposed sanctions on En- zymeWorks’s counsel for unreasonably multiplying the proceedings and violating the local rules (“Sanctions Or- der”). The district court also held EnzymeWorks in con- tempt of a district court protective order and imposed sanctions for violating the order (“Contempt Order”). We affirm the Contempt Order and remand to allow the dis- trict court to vacate the Sanctions Order. BACKGROUND I On February 19, 2016, Codexis, Inc. (“Codexis”) sued EnzymeWorks, asserting patent infringement, trade secret misappropriation, and various state law claims. On Au- gust 11, 2017, Codexis filed a motion for leave to amend its complaint to add two new state law claims. EnzymeWorks opposed the motion. EnzymeWorks argued, among other things, that the proposed amendments were futile and would not survive a motion to dismiss. The district court determined that the proposed amendments were not futile and granted Codexis’s motion for leave on September 25, 2017. Three days later, Codexis filed a second amended complaint adding these new claims. On September 27, 2017, EnzymeWorks sought leave to file a motion for reconsideration of the district court’s order granting Codexis leave to amend the complaint. En- zymeWorks “raised the same argument [it raised in oppo- sition to Codexis’s motion for leave], without citing new CODEXIS, INC. v. ENZYMEWORKS, INC. 3

facts, new law or a manifest failure by the Court to consider such facts or law,” as required by the local rules. Codexis, Inc. v. EnzymeWorks, Inc., No. 3:16-cv-00826, 2017 WL 5992130, at *5 (N.D. Cal. Dec. 4, 2017). On October 9, 2017, EnzymeWorks filed a motion to dismiss the new claims, asserting the same arguments for a third time. On December 4, 2017, the district court issued the Sanctions Order. The court denied EzymeWorks’s motion for leave to file a reconsideration motion and motion to dis- miss and imposed sanctions on EnzymeWorks. The court ordered EnzymeWorks’s counsel to “pay plaintiff’s counsel $10,000 as a civil sanction for needlessly multiplying this litigation and violating the Local Rules.” Id. On February 5, 2018, the parties notified the district court that they had settled the underlying dispute and sub- mitted a stipulated consent judgment of patent infringe- ment and a stipulated permanent injunction. The parties also filed a stipulated protective order, which restricted the parties’ comments on the settlement. The district court ap- proved and entered the three stipulated orders. Pursuant to the settlement agreement, the court dismissed the re- maining claims with prejudice. In connection with the settlement, EnzymeWorks also filed an unopposed motion to vacate the Sanctions Order. The district court did not immediately act on the motion. On March 6, 2018, EnzymeWorks filed a notice of appeal with respect to the Sanctions Order. While the appeal was pending, the district court purported to vacate the Sanc- tions Order. II Immediately after the parties settled, and after entry of the district court’s protective order, EnzymeWorks is- sued a series of press releases. On February 20, 2018, Co- dexis filed a motion to hold EnzymeWorks “in contempt for 4 CODEXIS, INC. v. ENZYMEWORKS, INC.

violating the [stipulated protective order] because defend- ants issued press releases that did not use the agreed upon statement and that spun the litigation and parties in a way that the [stipulated protective order] was designed to avoid.” Codexis, Inc. v. EnzymeWorks, Inc., No. 3:16-cv- 00826, 2018 WL 1536655, at *1 (N.D. Cal. Mar. 29, 2018). On March 29, 2018, the district court issued the Con- tempt Order. The court found EnzymeWorks in contempt of the stipulated protective order and sanctioned En- zymeWorks. Specifically, the court (1) “award[ed] Co- dexis’s counsel the full amount of its reasonable attorneys’ fees and costs incurred in connection with these contempt proceedings and with their efforts to secure defendants’ compliance with the [stipulated protective order]”; and (2) ordered EnzymeWorks to retract the press releases and, in that same retraction, publish the following statement: EnzymeWorks has been ordered by the United States District Court for the Northern District of California to retract its prior statements and press releases pertaining in any way to the settlement of the lawsuit filed against it by Codexis, Inc. The Court has found EnzymeWorks’s prior statements on the matter were made IN VIOLATION OF A COURT ORDER, and the Court has found En- zymeWorks . . . IN CONTEMPT OF COURT as a result of those prior statements. Id. at *9. EnzymeWorks subsequently amended its March 6, 2018 notice of appeal to appeal the Contempt Order. III We have jurisdiction pursuant to 28 U.S.C. § 1292(c). When reviewing non-patent law issues, such as the impo- sition of sanctions or the standard for contempt, we apply the law of the regional circuit. The Ninth Circuit reviews a district court’s “decision to impose sanctions for contempt for an abuse of discretion.” In re Crystal Palace Gambling CODEXIS, INC. v. ENZYMEWORKS, INC. 5

Hall, Inc., 817 F.2d 1361, 1364 (9th Cir. 1987). “A con- tempt order will not be reversed unless [the court] ha[s] a definite and firm conviction that the court below committed a clear error of judgment in the conclusion it reached after it weighed the relevant factors.” Id. DISCUSSION I EnzymeWorks argues the district court abused its dis- cretion in holding it in contempt because its press releases did not violate the stipulated protective order. We disa- gree. A district court has the authority to punish “contempt of its authority,” including a party’s “[d]isobedience” of an “order.” 18 U.S.C. § 401(3); accord Int’l Union, United Mine Workers of Am. v. Bagwell, 512 U.S. 821, 831 (1994); Reebok Int’l Ltd. v. McLaughlin, 49 F.3d 1387, 1390 (9th Cir. 1995). Civil contempt “consists of a party’s disobedi- ence to a specific and definite court order by failure to take all reasonable steps within the party’s power to comply.” Reno Air Racing Ass’n, Inc. v. McCord, 452 F.3d 1126, 1130 (9th Cir. 2006) (quoting In re Dual–Deck Video Cassette Re- corder Antitrust Litig., 10 F.3d 693, 695 (9th Cir. 1993)).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Codexis, Inc. v. Enzymeworks, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/codexis-inc-v-enzymeworks-inc-cafc-2019.